Northside Capital Management LLC Acquires 750 Shares of Novartis AG (NYSE:NVS)

Northside Capital Management LLC boosted its holdings in Novartis AG (NYSE:NVS) by 29.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,296 shares of the company’s stock after buying an additional 750 shares during the period. Northside Capital Management LLC’s holdings in Novartis were worth $321,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Integral Health Asset Management LLC lifted its stake in shares of Novartis by 33.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $31,938,000 after purchasing an additional 75,000 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Novartis by 115.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock valued at $26,797,000 after purchasing an additional 124,111 shares during the last quarter. Bank of Montreal Can lifted its stake in Novartis by 343.5% in the second quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock valued at $70,652,000 after buying an additional 509,567 shares during the period. CWA Asset Management Group LLC lifted its stake in Novartis by 20.1% in the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock valued at $3,001,000 after buying an additional 5,164 shares during the period. Finally, Quantbot Technologies LP boosted its holdings in Novartis by 135.5% during the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after buying an additional 22,998 shares during the last quarter. 13.12% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on NVS shares. BMO Capital Markets upped their price target on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Finally, HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating and seven have given a hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $121.50.

Novartis Stock Performance

Shares of NVS stock opened at $99.05 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. Novartis AG has a 52 week low of $92.35 and a 52 week high of $120.92. The company’s 50 day moving average price is $101.13 and its two-hundred day moving average price is $109.19. The company has a market capitalization of $202.46 billion, a P/E ratio of 11.50, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same period last year, the business posted $1.74 earnings per share. On average, analysts expect that Novartis AG will post 7.63 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.